Home・Aktien・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

10.69 -3.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.63

Max

10.75

Schlüsselkennzahlen
By Trading Economics
Einkommen	106M -96M
Verkäufe	-8M 15M
EPS	-0.81
Gewinnspanne	-639.494
Angestellte	377
EBITDA	1.4M -94M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+77.15% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-159M 1.5B
Vorheriger Eröffnungskurs	14.3
Vorheriger Schlusskurs	10.69

Nachrichtenstimmung

By Acuity

18%

82%

28 / 340 Ranking in Healthcare

Intellia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Intellia Therapeutics Inc Prognose

Kursziel

By TipRanks

77.15% Vorteil

12-Monats-Prognose

Durchschnitt 18.92 USD 77.15%

Hoch 49 USD

Tief 8 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Intellia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Intellia Therapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

28 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.